Xerosis Vaginalis (Vaginal Dryness)
Overview
Xerosis vaginalis, commonly called vaginal dryness, is a condition in which the vaginal walls become thin, less lubricated, and less elastic. The change can cause discomfort, itching, burning, and pain during sexual activity. While the term “xerosis vaginalis” is used in medical literature, patients more often hear “vaginal atrophy” or “dry vagina.”
It most frequently affects women who are post‑menopausal, but it can also appear in younger women during periods of hormonal fluctuation (e.g., breastfeeding, hormonal contraceptive use, or after certain surgeries).
Prevalence: According to the North American Menopause Society, up to 50 % of post‑menopausal women experience some degree of vaginal dryness, with 20–30 % reporting symptoms severe enough to affect daily activities or sexual intimacy. Among pre‑menopausal women, the prevalence is lower (≈5–10 %) but rises sharply after age 45.[1] Mayo Clinic
Symptoms
The presentation can vary from mild irritation to severe pain. Common symptoms include:
- Dryness or a “sandpaper” feeling inside the vagina.
- Itching or burning that may worsen after intercourse or during urination.
- Dyspareunia (painful intercourse) – often described as a sharp or pulling sensation.
- Vaginal spotting after sexual activity due to micro‑tears.
- Increased urinary urgency or frequency caused by irritation of the urethra.
- Painful pelvic exams or difficulty inserting tampons.
- Reduced libido secondary to discomfort or fear of pain.
- Feeling of “tightness” or reduced vaginal elasticity.
Symptoms may be intermittent or constant and can worsen in dry climates, after hot showers, or with the use of irritating soaps.
Causes and Risk Factors
Hormonal Changes
- Estrogen deficiency – the primary driver. Estrogen maintains blood flow, collagen, and glycogen production in the vaginal epithelium.
- Menopause (natural or surgical), oophorectomy, and anti‑estrogen therapies (e.g., aromatase inhibitors, tamoxifen).
Medications
- Antihistamines, decongestants, and certain antidepressants (SSRIs) that reduce systemic moisture.
- Chemotherapy or radiation to the pelvic area.
- Long‑term use of topical corticosteroids in the genital region.
Medical Conditions
- Autoimmune diseases (Sjӧgren’s syndrome, lupus) that affect mucosal glands.
- Diabetes mellitus – can alter tissue hydration and increase infection risk.
- Chronic vulvovaginal infections that damage the epithelium.
Lifestyle & Environmental Factors
- Smoking – reduces blood flow and collagen synthesis.
- Excessive douching, use of scented hygiene products, or harsh soaps.
- Very low estrogen diets (e.g., extremely low‑fat, high‑protein regimes) may indirectly affect hormone balance.
Who Is at Higher Risk?
- Women > 45 years, especially within 5‑10 years after menopause.
- Women who have had a hysterectomy with removal of ovaries.
- Breast cancer survivors on anti‑estrogen therapy.
- Those with a personal or family history of autoimmune disease.
Diagnosis
Diagnosis is primarily clinical, based on history and a focused pelvic exam. The goal is to confirm xerosis, rule out infection, and identify contributing factors.
History Taking
- Onset, duration, and pattern of symptoms.
- Menstrual and menopausal status, hormone therapy use.
- Medication list, especially antihistamines, antidepressants, and cancer treatments.
- Sexual activity and associated pain.
- Personal hygiene practices.
Physical Examination
- Visual inspection of the vulva and vagina for pallor, thinning, loss of rugae, and reduced moisture.
- Speculum exam to assess vaginal wall fragility and to collect samples if infection is suspected.
- pH testing – a vaginal pH > 5.0 may suggest atrophic changes (normal: 3.8‑4.5).[2] CDC
Lab Tests (when indicated)
- Vaginal swab cultures for bacterial vaginosis, yeast, or Trichomonas.
- Hormone panel (serum estradiol, FSH) if menopausal status is unclear.
- Biopsy is rarely needed but may be performed if a lesion is suspicious for neoplasia.
Treatment Options
Treatment is individualized, aiming to restore moisture, improve elasticity, and address any reversible contributors.
Topical Therapies
- Moisturizers (e.g., Replens, Vagisil) – applied 2–3 times weekly for long‑term hydration.
- Lubricants – water‑based (e.g., K-Y Jelly) or silicone‑based (e.g., Astroglide) for immediate relief during intercourse.
- Topical estrogen (estradiol cream 0.01 % or vaginal tablet 10 µg) – improves epithelial thickness within 2‑4 weeks. Recommended for women without contraindications to estrogen.[3] North American Menopause Society
- Selective estrogen receptor modulators (SERMs) – such as ospemifene 60 mg oral daily, approved for moderate to severe dyspareunia.[4] FDA
Systemic Hormone Therapy
- Combined estrogen‑progestin or estrogen‑only therapy for women who need broader menopausal symptom control and have no contraindications (e.g., history of breast cancer, thromboembolism).
- Low‑dose transdermal estradiol (0.025 mg/day) may improve vaginal health with lower systemic risk.
Non‑Hormonal Prescription Options
- Prasterone (DHEA) intravaginal inserts 6.5 mg – converts locally to estrogen and testosterone, enhancing moisture without significant systemic absorption.
- Topical calcitriol (vitamin D analog) – under investigation, shows promise in small trials.
Procedural Interventions
- Laser therapy (fractional CO₂ or erbium‑YAG) – stimulates collagen remodeling; data show symptom improvement in 70–80 % of treated women, though long‑term safety is still being studied.[5] JAMA Netw Open
- Radiofrequency vaginal resurfacing – similar mechanism to laser with growing evidence.
- In refractory cases, vaginal dilator therapy may be used to maintain elasticity.
Lifestyle & Self‑Care Measures
- Stop smoking and limit alcohol.
- Avoid scented soaps, douches, and bubble baths.
- Use a water‑based, fragrance‑free lubricant during sex.
- Wear breathable cotton underwear and loose‑fitting clothing.
- Stay hydrated (≥ 8 cups water daily).
Living with Xerosis Vaginalis
Effective management combines medical treatment with practical daily habits.
- Establish a routine – apply a vaginal moisturizer at night; it works best on dry tissue.
- Plan ahead for intimacy – keep a small bottle of lubricant in the bathroom or bedside drawer.
- Pelvic floor exercises (Kegels) can improve blood flow, which may support tissue health.
- Communication – openly discuss symptoms with a partner; emotional support reduces anxiety and improves sexual satisfaction.
- Regular follow‑up – schedule a check‑up every 6–12 months to reassess therapy effectiveness and adjust as needed.
Prevention
While hormonal changes cannot be fully prevented, certain measures lower risk or delay onset:
- Maintain a healthy weight and engage in regular aerobic exercise (≥ 150 min/week).
- Consume a diet rich in phytoestrogens (soy, flaxseed, legumes) – modest evidence suggests they may modestly support vaginal tissue.
- Quit smoking; nicotine reduces vaginal blood flow.
- Limit use of systemic antihistamines or discuss alternatives with a physician.
- Consider low‑dose vaginal estrogen at the first sign of dryness if no contraindications exist.
Complications
If left untreated, xerosis vaginalis can lead to:
- Recurrent urinary tract infections (UTIs) – irritated urethra is more prone to bacterial colonization.
- Vulvovaginal infections – micro‑tears provide entry points for pathogens.
- Sexual dysfunction – chronic pain can cause avoidance of intercourse, leading to relationship strain.
- Poor quality of life – associated with sleep disturbance, mood changes, and decreased self‑esteem.
- Atrophic vaginitis – severe thinning may predispose to bleeding and ulceration.
When to Seek Emergency Care
Call 911 or go to the nearest emergency department if you experience any of the following:
- Sudden, severe pelvic or lower‑abdominal pain accompanied by fever (> 38 °C/100.4 °F).
- Heavy vaginal bleeding that does not stop after 30 minutes of firm pressure.
- Signs of sepsis – rapid heartbeat, chills, confusion, or a foul‑smelling discharge.
- Sudden loss of bladder control (incontinence) with pain.
- Severe allergic reaction after using a new vaginal product (hives, swelling of the face or throat, difficulty breathing).
References
- Mayo Clinic. “Vaginal dryness.” Updated 2023. mayoclinic.org
- Centers for Disease Control and Prevention. “Vaginal health and pH.” 2022. cdc.gov
- North American Menopause Society. “Hormone Therapy Position Statement.” 2021.
- U.S. Food & Drug Administration. “Ospemifene (Osphena) Prescribing Information.” 2022.
- R. C. M. et al., “Effectiveness of Fractional CO₂ Laser for Genitourinary Syndrome of Menopause,” JAMA Network Open, 2022.